The announcement of a $13 billion senior unsecured notes offering by Bristol Myers Squibb is a significant financial move, indicating the company's strategy to manage its debt profile efficiently. While this move is crucial for long-term financial health, the immediate impact on the stock price is likely to be neutral. Investors may view this as a positive step towards financial stability, but the increase in debt may also raise concerns about future financial flexibility.